Straits Times Index
3,316.65 +8.75 (+0.26%) Nikkei
39,071.48 +454.38 (+1.18%) Hang Seng
18,930.02 -265.58 (-1.38%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,514.51 +173.37 (+0.25%) CMC Crypto 200
1,512.51 -13.90 (-0.91%)
BioLineRx Ltd. (BLRX.TA)
| Previous close | 16.10 |
| Open | 16.00 |
| Bid | 15.70 x 255900 |
| Ask | 15.90 x 42900 |
| Day's range | 15.50 - 16.10 |
| 52-week range | 15.10 - 70.00 |
| Volume | |
| Avg. volume | 1,514,905 |
| Market cap | 188.257M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings date | 28 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireBioLineRx to Report First Quarter 2024 Results on May 28, 2024
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2024 on Tuesday, May 28, 2024, before the U.S. markets open.
PR NewswireBioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid pric
PR NewswireBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference,
